Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21786-21798

  D'Artista, Luana ^a,b   Bisso, Andrea ^a   Piontini, Andrea ^b   Doni, Mirko ^b   Verrecchia, Alessandro ^b   Kress, Theresia R ^a   Morelli, Marco J ^a   Del Sal, Giannino ^c,d   Amati, Bruno ^a,b   Campaner, Stefano ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Laboratorio Nazionale CIB LNCIB   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

C myc; Lymphoma; Pin1; Proliferation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; MYC PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; SERINE; SERINE 62; SHORT HAIRPIN RNA; THREONINE; THREONINE 58; UNCLASSIFIED DRUG; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENICITY; CELL CYCLE; CODON; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE TRANSFER; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTO ONCOGENE; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; LYMPHOMA; MAMMALIAN EMBRYO; METABOLISM; PROCEDURES; RNA INTERFERENCE; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION PROFILING; LYMPHOMA; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE;

EID: 84965049886     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7846     Document Type: Article

References (58)

1. Lu KP, Hanes SD and Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 1996; 380:544-547.
2. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC and Lu KP. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science. 1997; 278:1957-1960.
3. Ranganathan R, Lu KP, Hunter T and Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell. 1997; 89:875-886.
4. Lu KP and Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007; 8:904-916.
5. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14:2501-2514.
6. Sears R, Leone G, DeGregori J and Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999; 3:169-179.
7. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004; 6:308-318.
8. Gregory MA and Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000; 20:2423-2435.
9. Meyer N and Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8:976-990.
10. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP and Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005; 436:807-811.
11. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C and Del Sal G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002; 419:853-857.
12. Wulf GM, Liou YC, Ryo A, Lee SW and Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002; 277:47976-47979.
13. Sorrentino G, Mioni M, Giorgi C, Ruggeri N, Pinton P, Moll U, Mantovani F and Del Sal G. The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell Death Differ. 2013; 20:198-208.
14. Grison A, Mantovani F, Comel A, Agostoni E, Gustincich S, Persichetti F and Del Sal G. Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad Sci U S A. 2011; 108:17979-17984.
15. Mantovani F, Zannini A, Rustighi A and Del Sal G. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships. Biochim Biophys Acta. 2015; 1850:2048-2060.
16. Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999; 13:2658-2669.
17. Sanchez-Arevalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Faga G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazzarol G, Peg V, Losa JH, Ronchi P, Ponzoni M, et al. Dual regulation of Myc by Abl. Oncogene. 2013; 32:5261-5271.
18. Farrell AS, Pelz C, Wang X, Daniel CJ, Wang Z, Su Y, Janghorban M, Zhang X, Morgan C, Impey S and Sears RC. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol. 2013; 33:2930-2949.
19. Min SH, Lau AW, Lee TH, Inuzuka H, Wei S, Huang P, Shaik S, Lee DY, Finn G, Balastik M, Chen CH, Luo M, Tron AE, et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell. 2012; 46:771-783.
20. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004; 101:9085-9090.
21. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23:2116-2125.
22. Fujimori F, Takahashi K, Uchida C and Uchida T. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun. 1999; 265:658-663.
23. Atchison FW, Capel B and Means AR. Pin1 regulates the timing of mammalian primordial germ cell proliferation. Development. 2003; 130:3579-3586.
24. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD and Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985; 318:533-538.
25. Langdon WY, Harris AW, Cory S and Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986; 47:11-18.
26. Vaux DL, Adams JM, Alexander WS and Pike BL. Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice. J Immunol. 1987; 139:3854-3860.
27. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998; 12:2424-2433.
28. Eilers M, Schirm S and Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 1991; 10:133-141.
29. Perna D, Faga G, Verrecchia A, Gorski MM, Barozzi I, Narang V, Khng J, Lim KC, Sung WK, Sanges R, Stupka E, Oskarsson T, Trumpp A, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene. 2012; 31:1695-1709.
30. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjo S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010; 12:54-59; sup pp 51-14.
31. Ryo A, Liou YC, Lu KP and Wulf G. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci. 2003; 116:773-783.
32. Munoz-Espin D and Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014; 15:482-496.
33. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM and Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002; 9:1031-1044.
34. Reimann M, Loddenkemper C, Rudolph C, Schildhauer I, Teichmann B, Stein H, Schlegelberger B, Dorken B and Schmitt CA. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood. 2007; 110:2996-3004.
35. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, Confalonieri S, Cesaroni M, Marchesi F, et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature. 2007; 448:1063-1067.
36. Campisi J and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740.
37. Lee TH, Tun-Kyi A, Shi R, Lim J, Soohoo C, Finn G, Balastik M, Pastorino L, Wulf G, Zhou XZ and Lu KP. Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol. 2009; 11:97-105.
38. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L and Evan GI. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008; 14:447-457.
39. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004; 3:1133-1137.
40. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Faga G, Bianchi V, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014; 511:488-492.
41. Frank SR, Schroeder M, Fernandez P, Taubert S and Amati B. Binding of c-Myc to chromatin mediates mitogeninduced acetylation of histone H4 and gene activation. Genes Dev. 2001; 15:2069-2082.
42. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR and Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999; 13:2670-2677.
43. Martins CP, Brown-Swigart L and Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006; 127:1323-1334.
44. Wulf G, Garg P, Liou YC, Iglehart D and Lu KP. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J. 2004; 23:3397-3407.
45. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V and Lu KP. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001; 20:3459-3472.
46. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP and Wang DG. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 2004; 164:1727-1737.
47. Farrell AS and Sears RC. MYC degradation. Cold Spring Harb Perspect Med. 2014; 4.
48. Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H, Dorken B, Jenuwein T and Schmitt CA. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010; 17:262-272.
49. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Moroy T, Felsher DW and Eilers M. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev. 2010; 24:1281-1294.
50. Kress TR, Sabo A and Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015; 15:593-607.
51. Tatara Y, Lin YC, Bamba Y, Mori T and Uchida T. Dipentamethylene thiuram monosulfide is a novel inhibitor of Pin1. Biochem Biophys Res Commun. 2009; 384:394-398.
52. Campaner S, Doni M, Verrecchia A, Faga G, Bianchi L and Amati B. Myc, Cdk2 and cellular senescence: Old players, new game. Cell Cycle. 2010; 9:3655-3661.
53. Fellmann C, Zuber J, McJunkin K, Chang K, Malone CD, Dickins RA, Xu Q, Hengartner MO, Elledge SJ, Hannon GJ and Lowe SW. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell. 2011; 41:733-746.
54. Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI. A modified oestrogen receptor ligandbinding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995; 23:1686-1690.
55. Hardy RR and Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001; 19:595-621.
56. Li M, He Y, Dubois W, Wu X, Shi J and Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell. 2012; 46:30-42.
57. Lauzon W, Sanchez Dardon J, Cameron DW and Badley AD. Flow cytometric measurement of telomere length. Cytometry. 2000; 42:159-164.
58. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, Sinha N and Zuber J. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013; 5:1704-1713.